What is the Impact of COVID-19 on Patients with Diabetes?
The CDC revealed that approximately 25% of hospital patients diagnosed with severe COVID-19 infections are diabetics. In addition, recent studies show that people with diabetes are four-times more likely to have serious/fatal complications from COVID-19 due to the fact that high blood sugar weakens the immune system, lessening the body’s ability to fight infections. A diabetes patient’s risk of severe COVID-19 infection is even greater if they have a concomitant heart condition or lung disease.
A 360° view of the diabetes patient’s journey enhances pharma’s decision-making capabilities. Using timely real-world evidence (RWE), pharmas are able to think and plan more strategically about sales and marketing efforts – including physician targeting and patient communication strategies.
MSA’s Healthcare Data Management experts provide solutions that empower pharma to better understand the impact of COVID-19 on the diabetes patient journey by linking clinical lab results, prescriptions, EMR, and medical claims data – all while protecting patient privacy.
MSA, provider of the industry’s most credentialed, configurable, and trusted de-identification and data management solutions, accurately anonymizes and seamlessly links disparate data from one or multiple sources, enabling total interoperability in a HIPAA-compliant manner. MSA helps answer healthcare’s most critical questions in real-time.
Contact the HCDM Team for more information about the industry’s most credentialed, configurable, and trusted healthcare data management solutions.
